Advertisement

Effect of a sequential oral contraceptive on plasma insulin and blood glucose levels after 6 months' treatment

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Blood glucose and plasma insulin levels were measured during an intravenous glucose tolerance test performed on 35 subjects both in a control state and during the sixth cycle of treatment with a sequential type of oral contraceptive. It was found that the blood glucose was slightly lowered in the drug-treated group, that plasma insulin levels were significantly elevated by the drug, and that this change is unrelated to the subject's weight change, family history of diabetes mellitus, or past obstetric history. The significance of these findings is discussed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Waine H.
        • Frieden E.H.
        • Caplan H.I.
        • Cole T.
        Arthr. & Rheumat. 1963; 6: 796
        • Gershberg H.
        • Javier Z.
        • Hulse M.
        Diabetes. 1964; 13: 378
        • Spellacy W.N.
        • Schoeller K.L.
        Clin. Res. 1965; 13: 407
        • Spellacy W.N.
        • Carlson K.L.
        Am. J. Obst. & Gynec. 1966; 95: 474
        • Peterson W.F.
        • Steel M.W.
        • Coyne R.V.
        Am. J. Obst. & Gynec. 1966; 95: 484
        • Wynn V.
        • Doar II, J.W.
        Lancet. 1966; 2: 715
        • Posner N.A.
        • Silverstone F.A.
        • Pomerance W.
        • Baumgold D.
        Obst. & Gynec. 1967; 29: 79
        • Posner N.A.
        • Silverstone F.A.
        • Pomerance W.
        • Singer N.
        Obst. & Gynec. 1967; 29: 87
        • Spellacy W.N.
        • Carlson K.L.
        • Birk S.A.
        Diabetes. 1967; 16: 590
        • Nelson N.
        J. Biol. Chem. 1944; 153: 375
        • Somogyi M.
        J. Biol. Chem. 1945; 160: 69
        • Goetz F.C.
        • Greenberg B.Z.
        • Ells J.
        • Meinert C.
        J. Clin. Endocrinol. 1963; 23: 1237
      1. (L. M. Hellman, Chairman)FDA Report on the oral contraceptives by the Advisory Committee on Obstetrics and Gynecology. 1966: 5
        • Spellacy W.N.
        • Carlson K.L.
        • Schade S.L.
        Am. J. Obst. & Gynec. 1967; 99: 382
        • Banks A.L.
        Greenblatt R.B. Progress in Conception Control. J. B. Lippincott Company, Philadelphia1966: 41
        • Beaton J.H.
        West. J. Surgl. 1964; 72: 160
        • Young Jr., C.C.
        • Mammen E.F.
        • Spain W.T.
        Pacific Med. & Surg. 1965; 73: 35
        • Jackson J.L.
        Greenblatt R.B. Progress in Conception Control. J. B. Lippincott Company, Philadelphia1966: 69
        • Spellacy W.N.
        • Carlson K.L.
        • Schade S.L.
        Clin. Res. 1967; 15: 330